$6.33
▲ +365.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Outlook Therapeutics in the last 3 months. The average price target is $6.33, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 365.69% upside from the last price of $1.36.
The current consensus among 4 contributing investment analysts is to buy stock in Outlook Therapeutics.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.
Read More